ADB-BINACA

Add links
Source: Wikipedia, the free encyclopedia.

ADB-BINACA
Legal status
Legal status
Identifiers
  • N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-benzyl-1H-indazole-3-carboxamide
JSmol)
  • O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3
  • InChI=1S/C21H24N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h4-12,18H,13H2,1-3H3,(H2,22,26)(H,23,27)
  • Key:IUFIUAWRCUVUCQ-UHFFFAOYSA-N

ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards

binding affinity (Ki) of 0.33 nM and an EC50 of 14.7 nM.[3]

ADB-BUTINACA

The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound.[4][5][6][7][8] It is a similarly potent CB1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC50 of 6.36 nM for CB1.[9][10]

See also

References

  1. S2CID 253396419
    .
  2. PMID 26793280
    .
  3. ^ WO 2009106982, "Indazole Derivatives" 
  4. PMID 34341821
    .
  5. PMID 34387654
    .
  6. S2CID 244490343
    .
  7. S2CID 247501663
    .
  8. S2CID 251444625
    .
  9. S2CID 227246346
    .
  10. PMID 33787091
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=ADB-BINACA&oldid=1208065322"